Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Assets (2016 - 2025)

Marker Therapeutics has reported Assets over the past 12 years, most recently at $19.1 million for Q4 2025.

  • Quarterly Assets fell 13.4% to $19.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.1 million through Dec 2025, down 13.4% year-over-year, with the annual reading at $19.1 million for FY2025, 13.4% down from the prior year.
  • Assets was $19.1 million for Q4 2025 at Marker Therapeutics, down from $21.7 million in the prior quarter.
  • Over five years, Assets peaked at $88.4 million in Q1 2021 and troughed at $10.9 million in Q3 2024.
  • The 5-year median for Assets is $22.0 million (2023), against an average of $35.5 million.
  • Year-over-year, Assets surged 106.04% in 2021 and then crashed 58.04% in 2023.
  • A 5-year view of Assets shows it stood at $68.1 million in 2021, then crashed by 49.48% to $34.4 million in 2022, then crashed by 50.24% to $17.1 million in 2023, then grew by 28.58% to $22.0 million in 2024, then dropped by 13.4% to $19.1 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Assets are $19.1 million (Q4 2025), $21.7 million (Q3 2025), and $14.8 million (Q2 2025).